Literature DB >> 2912742

Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias.

C A Savary1, E Lotzová.   

Abstract

We have shown that peripheral blood (PB) lymphocytes of normal donors inhibit colony formation by myeloid (K-562) and lymphoid (Molt-4) leukemia cell lines in a clonogenic assay in vitro. The inhibitor cells were identified as natural killer (NK) cells based on their large granular lymphocyte (LGL) morphology and CD16+CD5- cell surface phenotype. The levels of inhibition were dependent both on the leukemia: effector (L:E) cell ratio, as well as on the time of preincubation of the leukemic and effector cells; maximum inhibition was observed at a 1:20 L:E cell ratio, and required 6-16 h preincubation of the leukemia and effector cells. Colony formation of both K-562 and Molt-4 was also inhibited by a soluble factor derived from coculture of K-562 and PB lymphocytes. The finding that the growth of clonogenic Molt-4 cells was almost completely abolished following treatment with interferon (IFN)-alpha rA in the dose of 10(3) U/ml, whereas growth of K-562 cells was only slightly affected by similar treatment, suggested that NK cells may mediate inhibition of clonogenic leukemias through various mechanisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912742

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  3 in total

1.  Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease.

Authors:  B Glass; L Uharek; W Gassmann; B Focks; H Bolouri; H Loeffler; W Mueller-Ruchholtz
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution.

Authors:  M B Vidriales; A Orfao; M C López-Berges; M González; J M Hernandez; J Ciudad; A López; M J Moro; M Martínez; J F San Miguel
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

3.  Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Authors:  Maria R Baer; Stephen L George; Michael A Caligiuri; Ben L Sanford; Sandra M Bothun; Krzysztof Mrózek; Jonathan E Kolitz; Bayard L Powell; Joseph O Moore; Richard M Stone; John Anastasi; Clara D Bloomfield; Richard A Larson
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.